HK Stock Market Move | CSTONE PHARMA-B (02616) surged over 12% in the afternoon. The company announced four-year follow-up data on sugulimab at the ESMO annual meeting.

CSTONE PHARMA-B(02616) rose more than 12% in the afternoon, up 10.07% to 1.64 Hong Kong dollars as of the time of writing, with a turnover of 2.1132 million Hong Kong dollars. On the news front, Cornerstone Pharmaceuticals announced at noon that the long-term treatment and survival data of the GEMSTONE-302 study with the monoclonal antibody squamous cell glycoprotein (marketed as Zegjemy) combined with platinum-containing chemotherapy had been presented at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting. The four-year follow-up data further confirmed the significant long-term benefits of squamous cell glycoprotein combined with platinum-containing chemotherapy as first-line treatment for stage IV NSCLC. It is worth noting that in July of this year, the European Commission officially approved squamous cell glycoprotein (marketed as Cejemly) combined with platinum-containing chemotherapy for first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) without EGFR sensitive mutations or ALK, ROS1, RET genomic tumor variations. This is the first successful overseas entry of a domestically produced PD-L1 and a key breakthrough in Cornerstone Pharmaceuticals' global strategy.